Is Sotolaxibu included in medical insurance?

Sotorasib is a targeted drug used to treat patients with advanced non-small cell lung cancer (NSCLC) carrying the KRAS G12C mutation. KRAS G12CMutation is a common and difficult-to-treat gene mutation in lung cancer. As the first approved KRAS G12C inhibitor, sotoraxib selectively inhibits the activity of KRAS G12C protein, preventing the growth of cancer cells and significantly extending the progression-free survival of patients, providing a new treatment option for this group.

Currently, sotorasibu is not available in mainland China and is therefore not included in China’s medical insurance catalog. Domestic patients are temporarily unable to purchase the drug through formal channels, but they can obtain it through overseas drug purchase channels. The price of sotoracib is relatively high in overseas markets, and the price of the original drug varies slightly depending on the region. Taking the European and Hong Kong versions of original drugs as examples, their prices usually range from tens of thousands of yuan, which is a heavy burden for many patients.

However, generic versions of sotoraxib have been launched in some countries and regions, becoming a choice for more patients. The prices of generic drug brands in Laos, such as Lucius and Sotorasibu generic drugs produced by Big Bear Pharmaceuticals, have been reduced recently, ranging from more than one thousand yuan to more than two thousand yuan. The active ingredients of these generic drugs are the same as those of the brand-name drugs, providing an affordable alternative so that more patients can receive relatively effective treatments.

If domestic patients need to use sotoraxib, they usually choose to purchase generic drugs from overseas markets such as Laos and India to meet their treatment needs. With the global promotion of sotoracib, it is more likely to be launched in China in the future. By then, the chances of being included in medical insurance will also increase, thus reducing the financial burden on patients.